PubMed

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.

Kalbag JB, Walter YH, Nedelman JR, McLeod JF.

Diabetes Care. 2001 Jan;24(1):73-7.PMID: 11194245 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.

Dunning BE, Deacon R, Gutierrez C, Paladini S, Valentin MA, Foley JE.

Diabetologia. 2003 Mar;46 Suppl 1:M22-9. Epub 2002 Nov 9.PMID: 12652355 [PubMed - indexed for MEDLINE]Related articles

Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.

Luzio SD, Anderson DM, Owens DR.

J Clin Endocrinol Metab. 2001 Oct;86(10):4874-80.PMID: 11600556 [PubMed - indexed for MEDLINE]Related articlesFree article

Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.

Walter YH, Spratt DI, Garreffa S, McLeod JF.

Eur J Clin Pharmacol. 2000 May;56(2):129-33.PMID: 10877006 [PubMed - indexed for MEDLINE]Related articles

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

Hanefeld M, Bouter KP, Dickinson S, Guitard C.

Diabetes Care. 2000 Feb;23(2):202-7.PMID: 10868832 [PubMed - indexed for MEDLINE]Related articlesFree article

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.

Scheen AJ.

Clin Pharmacokinet. 2007;46(2):93-108. Review.PMID: 17253883 [PubMed - indexed for MEDLINE]Related articles

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

Karara AH, Dunning BE, McLeod JF.

J Clin Pharmacol. 1999 Feb;39(2):172-9.PMID: 11563410 [PubMed - indexed for MEDLINE]Related articles

The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.

Anderson D, Shelley S, Kellett N, Marshall D, Nimmo W.

Clin Ther. 2003 Jun;25(6):1722-38.PMID: 12860494 [PubMed - indexed for MEDLINE]Related articles

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.PMID: 15161773 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

Gribble FM, Manley SE, Levy JC.

Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.

Juhl CB, Pørksen N, Hollingdal M, Sturis J, Pincus S, Veldhuis JD, Dejgaard A, Schmitz O.

Diabetes Care. 2000 May;23(5):675-81.PMID: 10834429 [PubMed - indexed for MEDLINE]Related articlesFree article

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.

Malaisse WJ.

Treat Endocrinol. 2003;2(6):401-14. Review.PMID: 15981944 [PubMed - indexed for MEDLINE]Related articles

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF.

J Clin Endocrinol Metab. 2000 Mar;85(3):1081-6.PMID: 10720043 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.

González-Ortiz M, Hernández-Salazar E, Martínez-Abundis E.

J Diabetes Complications. 2005 Nov-Dec;19(6):356-60.PMID: 16260353 [PubMed - indexed for MEDLINE]Related articles

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2008 Nov;18(11):937-42.PMID: 18854776 [PubMed - indexed for MEDLINE]Related articles

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.

Owens DR, Luzio SD, Ismail I, Bayer T.

Diabetes Care. 2000 Apr;23(4):518-23.PMID: 10857945 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article